Nicola Wolstenholme
Deputy Director at EMQN CIC- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
Topline Score
Bio
Credentials
-
Directors Development Programme
In Professional Development (InPD)Sep, 2022- Nov, 2024
Experience
-
EMQN CIC
-
United Kingdom
-
Hospitals and Health Care
-
1 - 100 Employee
-
Deputy Director
-
Mar 2014 - Present
EMQN Deputy Director and Quality Manager EMQN Deputy Director and Quality Manager
-
-
-
Manchester University NHS Foundation Trust
-
United Kingdom
-
Hospitals and Health Care
-
700 & Above Employee
-
Clinical Scientist (Molecular Genetics/Molecular Pathology)
-
Feb 2003 - Mar 2014
Clinical Scientist specialist in Hereditary Cancers (FAP, HNPCC, BRCA1/2 (HBOC)), Molecular Pathology (lung, colon cancer and melanoma), Charcot Marie Tooth Disease (CMT), Congental adrenal hyperplasia (CAH). As a Clinical Scientist I was responsible for all aspects of testing from the assessment of referrals to the reporting of results whilst giving advice to clinicians on all aspects of testing. Additionally I was responsible for monitoring of quality and timeliness of these services and the planning and implementation of new scientific developments.
-
-
Regional Training Officer
-
Apr 2008 - Apr 2011
Delivering training co-ordination, advice and assessment for Scientific and Technical Trainees in Clinical Molecular Genetics for the northern region.
-
-
-
Somerset NHS Foundation Trust
-
United Kingdom
-
Hospitals and Health Care
-
700 & Above Employee
-
Clinical Audit Facilitator
-
Apr 2001 - Feb 2003
I promoted and managed clinical audit projects within the NHS/social care partnership overseeing projects from the planning stage, through to data gathering, analysis and dissemination of results. I subsequently developed and monitored action plans, with a focus on practical change. I was also responsible for providing audit advice and training across the trust. I promoted and managed clinical audit projects within the NHS/social care partnership overseeing projects from the planning stage, through to data gathering, analysis and dissemination of results. I subsequently developed and monitored action plans, with a focus on practical change. I was also responsible for providing audit advice and training across the trust.
-
-
-
Southmead Hospital
-
Research Services
-
100 - 200 Employee
-
Clinical Scientist (Molecular Gentics)
-
Jul 1995 - Oct 1999
Clinical Scientist responsible for service provision for Molecular Genetics and Cytogenetics. Specialising in cystic fibrosis (CF), Fragile X syndrome (FRAXA), Prader Willi and Angelman syndrome (PWAS), Y chromosome micro-deletions and karyotype analysis of amniotic fluid cell cultures. Clinical Scientist responsible for service provision for Molecular Genetics and Cytogenetics. Specialising in cystic fibrosis (CF), Fragile X syndrome (FRAXA), Prader Willi and Angelman syndrome (PWAS), Y chromosome micro-deletions and karyotype analysis of amniotic fluid cell cultures.
-
-
-
-
Clinical Scientist (Senior scientist in Clinical Molecular Genetics)
-
Jul 1987 - Jul 1995
Clinical Scientist specialising in cystic fibrosis (CF), Fragile X syndrome (FRAXA), Huntington disease (HD), Duchenne/Becker muscular dystropphy (DMD/BMD). As an original member of the lab I was responsible for developing many of the tests and services and for training new members of staff. Clinical Scientist specialising in cystic fibrosis (CF), Fragile X syndrome (FRAXA), Huntington disease (HD), Duchenne/Becker muscular dystropphy (DMD/BMD). As an original member of the lab I was responsible for developing many of the tests and services and for training new members of staff.
-
-
Education
-
1982 - 1986
The University of Salford
BSc, Biological and Biochemical Sciences (Applied)
Community
